Fifth Third Bancorp trimmed its holdings in Exelon Co. (NASDAQ:EXC – Free Report) by 1.6% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 198,050 shares of the company’s stock after selling 3,282 shares during the quarter. Fifth Third Bancorp’s holdings in Exelon were worth $8,296,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Asset Dedication LLC grew its stake in shares of Exelon by 17.6% during the 1st quarter. Asset Dedication LLC now owns 25,791 shares of the company’s stock valued at $1,091,000 after purchasing an additional 3,852 shares during the period. Harbor Investment Advisory LLC grew its stake in shares of Exelon by 18.1% during the 1st quarter. Harbor Investment Advisory LLC now owns 11,730 shares of the company’s stock valued at $491,000 after purchasing an additional 1,794 shares during the period. RNC Capital Management LLC grew its stake in shares of Exelon by 12.9% during the 1st quarter. RNC Capital Management LLC now owns 9,373 shares of the company’s stock valued at $393,000 after purchasing an additional 1,073 shares during the period. Avantax Planning Partners Inc. bought a new stake in shares of Exelon during the 1st quarter valued at about $205,000. Finally, Quad Cities Investment Group LLC grew its stake in shares of Exelon by 27.7% during the 1st quarter. Quad Cities Investment Group LLC now owns 6,146 shares of the company’s stock valued at $257,000 after purchasing an additional 1,333 shares during the period. 80.52% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
EXC has been the subject of a number of recent research reports. Guggenheim upgraded Exelon from a “neutral” rating to a “buy” rating and set a $44.00 price objective for the company in a research note on Friday. JPMorgan Chase & Co. decreased their target price on shares of Exelon from $50.00 to $46.00 in a research note on Wednesday, June 7th. Morgan Stanley raised their target price on shares of Exelon from $46.00 to $49.00 and gave the stock an “overweight” rating in a research note on Thursday, April 20th. The Goldman Sachs Group started coverage on shares of Exelon in a research note on Wednesday, June 7th. They set a “sell” rating and a $39.00 target price on the stock. Finally, Mizuho decreased their target price on shares of Exelon from $46.00 to $45.00 in a research note on Tuesday, May 16th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. According to MarketBeat, Exelon has a consensus rating of “Moderate Buy” and a consensus price target of $44.90.
Exelon Trading Down 0.2 %
Exelon (NASDAQ:EXC – Free Report) last issued its quarterly earnings results on Wednesday, May 3rd. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.66 by $0.04. The company had revenue of $5.56 billion for the quarter, compared to the consensus estimate of $5.52 billion. Exelon had a net margin of 11.61% and a return on equity of 9.41%. As a group, analysts anticipate that Exelon Co. will post 2.36 earnings per share for the current year.
Exelon Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 9th. Investors of record on Monday, May 15th were issued a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a yield of 3.52%. The ex-dividend date of this dividend was Friday, May 12th. Exelon’s payout ratio is currently 64.00%.
Exelon Company Profile
Exelon Corporation, a utility services holding company, engages in the energy distribution and transmission businesses in the United States and Canada. The company is involved in the purchase and regulated retail sale of electricity and natural gas, transmission and distribution of electricity, and distribution of natural gas to retail customers.
See Also
- Five stocks we like better than Exelon
- MarketBeat Week in Review – 7/3 – 7/7
- Pfizer Just Invested $25 million In This Biotech
- Cracks In The Labor Market? Not Yet, But They’re Coming
- Levi’s: Buy On The Dip Or Downtrend In Play?
- Who Wins And Who Loses With China’s Metal Restrictions
Want to see what other hedge funds are holding EXC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelon Co. (NASDAQ:EXC – Free Report).
Receive News & Ratings for Exelon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelon and related companies with MarketBeat.com's FREE daily email newsletter.